DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Sarcopenia Market Share @
Key Takeaways from the Sarcopenia Market Report
- The Sarcopenia Market Size in the 7MM is expected to grow from USD 2,276 million in 2025 to USD 5,626 million in 2034 at a CAGR of 10.6%.
- As per DelveInsight analysis, the Sarcopenia Market is anticipated to witness growth at a considerable CAGR driven by aging population and emerging therapies.
- The leading Sarcopenia Companies such as TTNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, and others.
- Promising Sarcopenia Therapies such as MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, and others.
Stay ahead in the Sarcopenia Therapeutics Market with DelveInsight’s Strategic Report @
Sarcopenia Epidemiology Segmentation in the 7MM
The epidemiology section of Sarcopenia offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries.
The Sarcopenia Diagnosed Prevalent Cases in the 7MM were nearly ~19,836,200 in 2024 and are projected to increase during the study period (2020–2034).
In Japan, the cases of sarcopenia account for approximately ~5,225,100 in 2024. Among the EU4 and the UK, the UK accounted for the highest number of sarcopenia diagnosed prevalent cases.
Download the report to understand which factors are driving Sarcopenia Epidemiology trends @ Sarcopenia Prevalence
Sarcopenia Drugs Market
The Sarcopenia Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Currently, there are no approved drugs; management relies on exercise and nutrition. Sarcopenia impacted nearly 15 million people in the 7MM in 2024.
Sarcopenia Treatment Market Landscape
The Sarcopenia treatment market landscape has witnessed significant advancements, though no pharmacologic therapies are approved. Focus is on muscle anabolic pathways with a pipeline including TNF-α inhibitors (MYMD-1), androgen receptor agonists (LPCN 1148), and MAS-1 agonists (Sarconeos). Physical exercise remains the only recommended option.
To learn more about Sarcopenia treatment guidelines, visit @ Sarcopenia Treatment Market Landscape
Sarcopenia Market Outlook
The report’s outlook on the Sarcopenia market aids in developing a comprehensive understanding of historical, current, and projected trends. The total market size was approximately USD ~2,200 million in 2024 and is projected to increase during 2025–2034, driven by first-in-class approvals like MYMD-1 and LPCN 1148.
Sarcopenia Drugs Uptake
The drug chapter provides a comprehensive analysis of marketed drugs (none currently) and late-stage pipeline drugs. Key assets: MYMD-1 (Phase II completed, Phase III planned), LPCN 1148 (FDA Fast Track Dec 2024), Sarconeos (Phase II).
Major Sarcopenia Companies
TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, and others.
Learn more about the emerging drugs for Sarcopenia @ Sarcopenia Companies
Scope of the Sarcopenia Market Report
- Coverage- Global
- Study Period- 2020-2034
- Sarcopenia Companies- TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, and others.
- Sarcopenia Therapies- MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510, and others.
- Sarcopenia Market Dynamics: Sarcopenia Market Drivers and Barriers
- Sarcopenia Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Sarcopenia Drugs in development @ Sarcopenia Clinical Trials Assessment
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Methodology
- Sarcopenia Market Overview at a Glance
- Disease Background and Overview
- Treatment and Management
- Epidemiology and Patient Population
- Patient Journey
- Emerging Drugs
- Sarcopenia: Seven Major Market Analysis
- Unmet Needs
- SWOT Analysis
- KOL Views
- Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
